Dermatomyositis post vaccine against SARS-COV2

Area of Science:

• Neurology
• Immunology
• Vaccinology

Background:

• Dermatomyositis is a rare idiopathic inflammatory myopathy affecting adults over 40, characterized by muscle weakness and skin manifestations.
• Its etiology remains unknown, complicating diagnosis and treatment strategies.
• The widespread use of COVID-19 vaccines (SARS-CoV-2) has raised awareness of potential rare adverse effects.

Purpose of the Study:

• To report a case of dermatomyositis with a temporal association following SARS-CoV-2 vaccination.
• To highlight the importance of monitoring and reporting potential vaccine-related adverse events in idiopathic inflammatory myopathies.

Main Methods:

• A case study detailing a patient vaccinated with BNT162b2 mRNA (Pfizer-BioNTech) for SARS-CoV-2.
• Diagnostic workup included electromyography, muscle biopsy, and laboratory tests to confirm dermatomyositis.
• The patient underwent standard treatment with steroid therapy.

Main Results:

• The patient presented with symptoms of dermatomyositis shortly after receiving the COVID-19 vaccine.
• Diagnostic investigations confirmed the diagnosis of dermatomyositis.
• The patient showed a slow but steady improvement with standard steroid treatment.

Conclusions:

• While a definitive causal link cannot be established, the temporal relationship suggests the COVID-19 vaccine may be a potential trigger for dermatomyositis.
• This case underscores the need to consider vaccination as a possible factor in new-onset idiopathic inflammatory myopathies.
• Further research is warranted to elucidate the potential association between SARS-CoV-2 vaccines and inflammatory myopathies.